These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16483497)

  • 21. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
    Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
    Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
    Sendur MA; Aksoy S; Zengin N; Altundag K
    J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
    Nagykálnai T
    Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Grana G
    J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anastrozole-resistant breast cancer responsive to exemestane--a case report].
    Sakurai T; Oura S; Hirai I; Tanino H; Yoshimas T; Kokawa Y; Nishida M; Sasaki R; Kinoshita T; Bessho T; Yokochi H; Nishimura O; Okamura Y
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2051-3. PubMed ID: 15570939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.
    Printz C
    Cancer; 2014 Oct; 120(19):2939-40. PubMed ID: 25241884
    [No Abstract]   [Full Text] [Related]  

  • 29. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
    Saladores PH; Precht JC; Schroth W; Brauch H; Schwab M
    Expert Rev Mol Diagn; 2013 May; 13(4):349-65. PubMed ID: 23638818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leuprolide acetate plus aromatase inhibition for male breast cancer.
    Giordano SH; Hortobagyi GN
    J Clin Oncol; 2006 Jul; 24(21):e42-3. PubMed ID: 16849742
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting breast cancer with hormonal treatment options.
    Mellington TE; Fields MM
    Nurse Pract; 2008 May; 33(5):17-22; quiz 22-3. PubMed ID: 18458623
    [No Abstract]   [Full Text] [Related]  

  • 35. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 36. Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
    Jinih M; Relihan N; Corrigan MA; O'Reilly S; Redmond HP
    Breast J; 2017 Nov; 23(6):694-705. PubMed ID: 28252242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer survivors.
    Boyle F; Forbes J
    Aust Fam Physician; 2008 Oct; 37(10):791. PubMed ID: 19013826
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-aromatase agents in the treatment and prevention of breast cancer.
    Goss P
    Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
    Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
    Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
    Semiglazov VF; Semiglazov VV; Dashian GA; Zhil'tsova EK; Ivanov VG; Bozhok AA; Tonuzov EE; Paltuev RM; Mel'nikova OA; Klettsel' AA; Krivorot'ko PV; Donskikh RV; Kochetova IA; Damenia AO; Zernov KIu; Voskresenskiĭ DA; Bershteĭn LM
    Vopr Onkol; 2007; 53(4):400-8. PubMed ID: 17969401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.